GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance

This Phase 2 study is testing whether a weekly injection of dulaglutide — a GLP-1 receptor agonist medication — can improve early insulin secretion and blood sugar control in people with cystic fibrosis (CF) who have abnormal glucose tolerance or CF-related diabetes (CFRD). Diabetes is a major complication of CF in people with pancreatic insufficiency and is linked to worse lung and overall health outcomes. Adults (18+) with confirmed CF, pancreatic insufficiency, and abnormal glucose results on a tolerance test — and who are willing to take a weekly subcutaneous injection — are eligible, though those with a BMI under 19, recent lung exacerbation, or prior organ transplant are excluded. Participation involves weekly injections for several weeks, a mixed-meal tolerance test, and regular monitoring for glucose, safety, and lung-related outcomes. This summary was prepared with AI assistance to help patients understand the study in plain language.